Ureteral Catheters Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Ureteral Catheters Market Trends and Insights

Rising Burden of Urolithiasis and Ureteral Obstruction

The clinical burden of urolithiasis provides a durable base of demand for the ureteral catheters market. The December 2025 meta-analysis estimated a pooled global prevalence of 10.85% across 1,276,826 (1.28 million) participants in 22 studies. It reported a prevalence of 12.93% among males and 8.91% among females, a difference that affects the mix of stone-management access procedures used by care providers. Asia recorded 11.8% prevalence, compared with 8.3% in North America, which points to substantial unmet procedural capacity in high-burden regions.^{[1]Source: “Global Prevalence of Urolithiasis: A Meta-Analysis Accounting for Methodological Heterogeneity,” Frontiers in Urology, frontiersin.org} Greater use of ureteroscopy and retrograde intrarenal surgery expands the patient base for catheter procedures. It also increases the addressable patient base across the ureteral catheters market as treatment pathways become more accessible.

Increasing Adoption of Minimally Invasive Urological Procedures

Flexible ureteroscopy and retrograde intrarenal surgery have raised the functional requirements for catheter systems used for access and working channels. A 2025 systematic review and meta-analysis found that flexible and navigable suction ureteral access sheaths achieved a day-1 stone-free rate relative risk of 2.12 against standard sheaths, with p=0.019.^{[2]Source: “Comparison Between Flexible and Navigable Suction Ureteral Access Sheath and Standard Ureteral Access Sheath During Flexible Ureteroscopy: Systematic Review and Meta-Analysis,” BMC Urology, springer.com} The same analysis reported 59% lower overall postoperative complications, with a relative risk of 0.41 and p<0.001. These results make suction capability and navigable tip performance more important in procurement decisions across the ureteral catheters market. The move toward disposable ureteroscopes also supports demand because each procedure requires a compatible access catheter within the procedural kit. The ureteral catheters market benefits when providers view the catheter as a necessary part of a single-use endourology workflow rather than as an isolated supply item.

Growth of Single-Use and Infection-Controlled Catheter Workflows

Infection prevention supports the shift toward individually sterile-packed catheter formats throughout the ureteral catheters market. The International Society for Infectious Diseases reported a catheter-associated urinary tract infection rate of 8.9 per 1,000 urinary catheter days in its 2024 update. The association also described catheter-associated urinary tract infection as an independent mortality risk factor. APIC stated in March 2025 that indwelling urinary catheters are used in up to 16% of hospitalized patients. A 2024 study across 299 intensive care units in 32 countries reported an 89% reduction in catheter-associated urinary tract infection rates after a multicomponent intervention, from 14.89 to 1.71 per 1,000 catheter days. These findings strengthen the case for short-duration, single-use protocols, although hospitals still weigh the higher per-procedure cost of advanced systems against budget limits.

Expansion of Ambulatory Urology and Same-Day Surgery

The movement of urological procedures from inpatient settings to outpatient facilities supports higher catheter use in standardized, high-volume settings. MedPAC reported 5,744 Medicare-certified ambulatory surgical centers in the United States in March 2025, including 152 single-specialty centers focused on urology. The total Medicare-certified ambulatory surgical center count had increased 25% over the prior decade. These facilities depend on ready-to-use products that can support predictable case flow and short room turnover times. Management service organizations that operate several urology facilities can also standardize purchasing and direct volume to preferred suppliers. This gives suppliers with a reliable outpatient product range an opportunity in the ureteral catheters market, while also increasing pressure on unit prices through consolidated purchasing.

Catheter-Related Infection, Trauma, and Encrustation Risk

Encrustation, biofilm formation, and insertion trauma limit use in long-indwelling and repeat-use scenarios across the ureteral catheters market. A 2025 in vitro study found a mean encrustation weight gain of 0.76±0.45 mg/mm for silicon-covered metallic ureteral stents and 1.30±0.81 mg/mm for PTFE-covered alternatives, with p=0.004. The result shows that material performance can differ substantially and can complicate procurement decisions. A separate 2025 randomized study found lower calcium and magnesium adherence on stents using Percushield and pHreeCoat technologies than on Hydroplus-coated controls. Material improvements can address some risks, but they also add cost and complicate product selection. Placement and retrieval can also cause ureteral trauma in patients with fragile tissue, which may limit the case for frequent exchanges.

Reimbursement and Hospital Cost-Containment Pressure

Bundled reimbursement structures can constrain spending on premium catheter products in the ureteral catheter market. In Germany, the 2025 Hybrid DRG framework included ureteral stone removal among the covered procedures, which kept catheter costs within a fixed case payment. This encourages providers to select lower-cost alternatives when clinical outcome data do not clearly justify a premium. In the United States, payment penalties associated with elevated catheter-associated urinary tract infection rates create a separate financial pressure on hospitals. Providers must control infection-related costs while also limiting the per-procedure spend on catheter systems. This tension can slow uptake of higher-specification designs even when their clinical rationale is strong.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

Open-end ureteral catheters held 26.84% of the ureteral catheters market share in 2025, the largest share among product configurations. Their broad use in retrograde pyelography, ureter drainage, and pre-ureteroscopy catheterization supports steady procedural demand. Availability in several French sizes and from many suppliers supports clinical flexibility while sustaining competitive pricing and limiting revenue per unit. Ureteral access catheters are projected to record a 7.14% CAGR through 2031. Their growth reflects increased use of disposable flexible ureteroscopy and suction-enabled sheath systems across the ureteral catheters market.

Cook Medical commercially launches the Syfonix suction ureteral access sheath in March 2026 for the United States and Canada. The single-use sheath has inner diameters from 9 Fr to 12 Fr and provides fingertip suction control during ureteroscopic kidney stone management. Cook Medical also launches the 7.5 Fr Ascend single-use flexible ureteroscope with the product line. Closed-end and dual-lumen products retain defined roles in contrast injection and complex drainage, while balloon catheters remain linked to ureteral stricture dilation. Diagnostic and retrograde pyelography products continue to support imaging-oriented procedures in the ureteral catheters market.

By Material: PTFE Gains Share on Encrustation Performance

Polyurethane accounted for 38.57% of revenue in 2025 and remained the leading material type. Its pushability, tensile strength, memory effect, and kink resistance support use across many ureteral catheter designs. Hydrophilic or PTFE surface coatings can help polyurethane products address long-indwelling use while retaining their role against newer materials. PTFE-based materials are forecast to grow at a 6.68% CAGR through 2031. Their chemical inertness, low insertion friction, and resistance to biofilm adhesion support their uptake in the ureteral catheters market.

A 2025 study described water-dispersible antibacterial polyurethane coatings based on a piperazine formulation for medical catheters.^{[3]Source: “1,4-Bis(2-hydroxyethyl)piperazine-derived Water-Dispersible and Antibacterial Polyurethane Coatings for Medical Catheters,” Journal of Materials Chemistry B, rsc.org}This work showed that material choice and surface technology are becoming more closely linked. Silicone remains relevant for long-term stenting applications where biocompatibility and infection resistance are prioritized over column strength. Polyvinyl chloride and polyethylene continue to serve cost-sensitive purchasing environments, while nylon provides a more rigid alternative for diagnostic catheterization requiring consistent contrast delivery. The ureteral catheters industry, therefore, has material demand that varies by procedure duration, clinical need, and tender conditions.

By Application: Stone Management Integration Expands System-Level Catheter Demand

Ureteroscopy and stone management accounted for 31.46% of the ureteral catheters market size in 2025. This position reflects the need for catheterization at several stages of flexible ureteroscopy. A single case can involve an access sheath, a working-channel catheter, and a post-procedure double-J stent. The increasing use of disposable devices raises catheter consumption per procedure. Boston Scientific received FDA clearance for its Asurys Fluid Management System in March 2026, which regulates irrigation inflow in real time to help maintain intrarenal pressure during ureteroscopy with the LithoVue Elite single-use digital flexible ureteroscope.

Ureteral stenting is the fastest-growing application, with a projected CAGR of 6.91% through 2031. More frequent prophylactic post-ureteroscopy stenting can increase device use even after complete stone clearance. Urinary drainage remains a large and stable application in oncology, obstetric surgery, and pelvic surgery. These procedures need ureteral patency management and may require repeated catheterization, while diagnostic imaging and retrograde pyelography remain persistent applications in the ureteral catheters market. Clinical outcomes associated with suction access sheaths also affect stone management protocols, with the 2025 meta-analysis reporting 67% fewer postoperative fevers than standard sheaths, with a relative risk of 0.33 and p<0.001.

By End User: Hospitals Dominate Volume While ASCs Capture the Fastest Procedural Growth

Hospitals held 55.72% of end-user revenue in 2025. They remain the principal location for high-complexity urological care, including obstructive uropathy management, oncology-related stenting, and emergency catheterization after surgery. Group purchasing agreements and annual supply contracts create switching barriers for suppliers in the ureteral catheters market. These arrangements favor brands with validated products and dependable service. Specialty urology clinics and diagnostic or interventional radiology centers represent smaller but growing sources of demand when image-guided placement is needed for obstructed oncology patients.

Ambulatory surgical centers are forecast to grow at a 6.78% CAGR through 2031. Their expansion is supported by more outpatient capacity and broader reimbursement inclusion for urology procedures. MedPAC’s 2025 count of 152 Medicare-certified urology-only ambulatory surgical centers highlights the scale of this setting in the United States.^{[4]Source: “Ambulatory Surgical Center Services: Status Report,” Medicare Payment Advisory Commission, medpac.gov} These centers prefer ready-to-use single-use products that fit standardized operating processes. Urology management service organizations can concentrate stone-management volumes in affiliated centers, creating recurring purchasing patterns for preferred suppliers in the ureteral catheters market.

Geography Analysis

North America accounted for 37.94% of global revenue in 2025 and held the largest regional position in the ureteral catheters market. The United States supports high per-capita stone management procedure volumes and a developed reimbursement structure for urology services. The shift of procedures to ambulatory surgical centers is increasing catheter use at outpatient sites, and CMS issued a July 2025 payment system update for that setting. Canada maintains tertiary urology volumes through provincial health systems and tends to favor competitively priced disposable formats. Mexico is expanding through private-hospital capacity and broader insured population coverage under health system reform programs.

Asia-Pacific is projected to grow at a 7.22% CAGR through 2031, making it the fastest-growing region in the ureteral catheters market. Demographic aging, healthcare investment, and local manufacturing capacity support this trajectory. China benefits from expanding infrastructure, wider insurance coverage, stronger imaging access, and wider availability of advanced urology procedures beyond top-tier hospitals. Volume-based procurement can reduce prices for standard catheter formats while preserving interest in advanced coated and single-use designs that meet tender requirements. India is expanding urology infrastructure in tier-2 cities, while South Korea, Japan, GCC countries, Brazil, and Argentina add demand through advanced endourology, older populations, private hospitals, and tertiary care.

Europe contributed a significant share of revenue in 2025, with Germany, the United Kingdom, and France as major volume markets. Germany’s bundled payment structure for ureteral stone removal constrains premium device adoption when benefits are not clearly differentiated. NICE guidance on the Memokath 051 Ureter recommended prospective collection of data on patient selection, stent choice, and adverse events for ureteric obstruction management, supporting closer assessment of stent procedure outcomes. Italy, Spain, and the Nordic countries offer growing public-sector procedure volumes, while reimbursement limits and EU medical device rules affect the ureteral catheters market in Europe.